Results 81 to 90 of about 60,343,578 (236)
Clinical Trials Unit Newsletter - Issue 02 [PDF]
What\u27s inside this issue: The Clinical Trials Summit of Pakistan 2025 Biosimilar trials at CTU! Completion of the Panbio Self-Test Enrolment Coming Together for Better Cancer Care Informative Snippets Clinical Trials Unit celebrates Clinical Trials ...
Clinical Trials Unit (CTU),
core +1 more source
Molecular Oncology, EarlyView.The proposed mechanism of action for the CDK12/13 inhibitor and cyclin K degrader, CT7439. CDK12/13 inhibition interrupts transcription elongation, leading to increased DNA damage that results in cell death. This agent is a potentially novel treatment option for patients with colorectal cancer. Created in BioRender. Cyclin‐dependent kinase (CDK) 12 and
Wylie K. Watlington +10 more
wiley +1 more source
Molecular Oncology, EarlyView.Circulating microRNAs as biomarkers of cachexia and sex‐specific cancer in senior dogs. In 25 client‐owned dogs, four circulating miRNAs (miR‐15a, miR‐15b, miR‐16, miR‐140) were downregulated in cachexia, with miR‐16 the strongest individual biomarker (AUC = 0.899).
Soon‐Seok Park +6 more
wiley +1 more source
WITCO Desperadoes and Phase II Pan Groove Performing in USA
, 2013 Video: not that Clear; Audio: OK – Mono (Left side of stereo field has a light humming sound throughout)Abstract00:00 – Footage starts with a wide shot of Desperadoes on Stage01:00 – Cut to footage of “Dr.
Phase II Pan Groove +2 more
core
Understanding implementability in clinical trials: a pragmatic review and concept map.
BackgroundThe translation of evidence from clinical trials into practice is complex. One approach to facilitating this translation is to consider the 'implementability' of trials as they are designed and conducted.
Australian Clinical Trials Alliance Reference Group on Impact and Implementation of CTN Trials +5 more
core +1 more source
, 2012 The NHMRC Clinical Trials Centre (CTC) at the University of Sydney runs large multicentre investigator-initiated clinical trials, takes part in trials of national and international collaborative trial groups and contributes expertise to trials run by ...
NHMRC Clinical Trials Centre
core
Cancer‐associated mutations in endometriosis reframe a benign disease through molecular oncology
Molecular Oncology, EarlyView.This review aims to comprehensively analyse cancer‐associated somatic mutations (CAMs) present in endometriotic lesions, emphasizing their biological roles, spatial distribution and implications for translational applications in medicine. By contextualizing a benign state within a genomic framework, this analysis seeks to establish its value as a ...
Clarissa Mujacic +15 more
wiley +1 more source
Molecular Oncology, EarlyView.LUNAR is a liver‐specific long noncoding RNA (lncRNA) that is highly expressed in normal liver but becomes epigenetically silenced in hepatocellular carcinoma through promoter hypermethylation. Loss of LUNAR is associated with NOTCH activation, epithelial–mesenchymal transition, and metastasis, whereas restoring LUNAR restrains metastatic progression ...
Se Ha Jang +9 more
wiley +1 more source
Clinical Trials Unit Newsletter - Issue 01 [PDF]
What\u27s inside this issue: AKU receives JCIA reaccreditation - Clinical Trials Unit rejoice Director’s Message Informative Snippets AKU Site Surpasses Target Sample Size in the D-LIVR Global Trial Clinical Trials Unit celebrates World Pharmacists Day ...
Clinical Trials Unit (CTU),
core +1 more source
Translating whole‐genome doubling into precision medicine in cancer
Molecular Oncology, EarlyView.Whole‐genome doubling creates a WGD‐positive tumor state characterized by persistent chromosomal instability, karyotypic diversification, and cellular stress. These same biological pressures drive aggressive tumor evolution while exposing therapeutic vulnerabilities, providing a rationale for WGD‐informed precision medicine. Whole‐genome doubling (WGD)
Sejung Lee, Junghyeok Lim, Jinhyuk Bhin
wiley +1 more source